ESMO 2019: Cediranib Plus Olaparib Shows Promise in Platinum-Resistant Ovarian Cancer
A 5-day-per-week intermitted schedule of cediranib may jeopardize outcomes without increasing tolerability
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.